Long-term outcome with targeted therapy in advanced/metastatic HER2-positive breast cancer: The Royal Marsden experience
Published 2019 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Long-term outcome with targeted therapy in advanced/metastatic HER2-positive breast cancer: The Royal Marsden experience
Authors
Keywords
Breast cancer, HER2 positive, Trastuzumab, Advanced stage
Journal
BREAST CANCER RESEARCH AND TREATMENT
Volume -, Issue -, Pages -
Publisher
Springer Science and Business Media LLC
Online
2019-08-20
DOI
10.1007/s10549-019-05406-6
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- SOPHIA primary analysis: A phase 3 (P3) study of margetuximab (M) + chemotherapy (C) versus trastuzumab (T) + C in patients (pts) with HER2+ metastatic (met) breast cancer (MBC) after prior anti-HER2 therapies (Tx).
- (2019) Hope S. Rugo et al. JOURNAL OF CLINICAL ONCOLOGY
- 6 versus 12 months of adjuvant trastuzumab for HER2-positive early breast cancer (PERSEPHONE): 4-year disease-free survival results of a randomised phase 3 non-inferiority trial
- (2019) Helena M Earl et al. LANCET
- Treatment of advanced HER2-positive breast cancer: 2018 and beyond
- (2018) Noam Pondé et al. CANCER TREATMENT REVIEWS
- Targeted agents for HER2-positive breast cancer in older adults: current and future perspectives
- (2018) Enrique Soto-Perez-De-Celis et al. EXPERT OPINION ON INVESTIGATIONAL DRUGS
- Cardiotoxicity and Cardiac Monitoring Among Chemotherapy-Treated Breast Cancer Patients
- (2018) Mariana L. Henry et al. JACC-Cardiovascular Imaging
- Cost-Effectiveness of Pertuzumab in Human Epidermal Growth Factor Receptor 2–Positive Metastatic Breast Cancer
- (2016) Ben Y. Durkee et al. JOURNAL OF CLINICAL ONCOLOGY
- Cardiac Outcomes of Patients Receiving Adjuvant Weekly Paclitaxel and Trastuzumab for Node-Negative, ERBB2-Positive Breast Cancer
- (2016) Chau Dang et al. JAMA Oncology
- Long-term outcome of HER2 positive metastatic breast cancer patients treated with first-line trastuzumab
- (2015) B. Yeo et al. BREAST
- Pertuzumab, Trastuzumab, and Docetaxel in HER2-Positive Metastatic Breast Cancer
- (2015) Sandra M. Swain et al. NEW ENGLAND JOURNAL OF MEDICINE
- Long-term tumor remission under trastuzumab treatment for HER2 positive metastatic breast cancer – results from the HER-OS patient registry
- (2014) Isabell Witzel et al. BMC CANCER
- Recommendations for Human Epidermal Growth Factor Receptor 2 Testing in Breast Cancer: American Society of Clinical Oncology/College of American Pathologists Clinical Practice Guideline Update
- (2013) Antonio C. Wolff et al. JOURNAL OF CLINICAL ONCOLOGY
- 6 months versus 12 months of adjuvant trastuzumab for patients with HER2-positive early breast cancer (PHARE): a randomised phase 3 trial
- (2013) Xavier Pivot et al. LANCET ONCOLOGY
- Durable complete response following chemotherapy and trastuzumab for metastatic HER2-positive breast cancer
- (2012) G. Gullo et al. ANNALS OF ONCOLOGY
- Pertuzumab plus Trastuzumab plus Docetaxel for Metastatic Breast Cancer
- (2011) José Baselga et al. NEW ENGLAND JOURNAL OF MEDICINE
- American Society of Clinical Oncology/College of American Pathologists Guideline Recommendations for Immunohistochemical Testing of Estrogen and Progesterone Receptors in Breast Cancer
- (2010) M. Elizabeth H. Hammond et al. JOURNAL OF CLINICAL ONCOLOGY
- Prognosis of Women With Metastatic Breast Cancer byHER2Status and Trastuzumab Treatment: An Institutional-Based Review
- (2009) Shaheenah Dawood et al. JOURNAL OF CLINICAL ONCOLOGY
Create your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create NowBecome a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get Started